0.31
-0.0065(-2.07%)
Currency In USD
| Previous Close | 0.31 |
| Open | 0.33 |
| Day High | 0.41 |
| Day Low | 0.29 |
| 52-Week High | 1.43 |
| 52-Week Low | 0.24 |
| Volume | 4.46M |
| Average Volume | 1.71M |
| Market Cap | 18.12M |
| PE | -0.27 |
| EPS | -1.15 |
| Moving Average 50 Days | 0.74 |
| Moving Average 200 Days | 0.54 |
| Change | -0.01 |
If you invested $1000 in BioAtla, Inc. (BCAB) since IPO date, it would be worth $9.94 as of January 14, 2026 at a share price of $0.308. Whereas If you bought $1000 worth of BioAtla, Inc. (BCAB) shares 5 years ago, it would be worth $6.63 as of January 14, 2026 at a share price of $0.308.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
GlobeNewswire Inc.
Dec 31, 2025 12:00 PM GMT
BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla to retain 65% ownership of Oz-V across all solid
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
GlobeNewswire Inc.
Nov 21, 2025 5:25 AM GMT
These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnershipCompany is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to com
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
GlobeNewswire Inc.
Nov 07, 2025 2:00 PM GMT
— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec-V safety profile as monotherapy